Calidi Biotherapeutics (CLDI) Receivables (2022 - 2025)

Calidi Biotherapeutics' Receivables history runs 4 years deep, the most recent figure standing at $100000.0 for Q2 2025.

• In Q2 2025, Receivables fell 73.75% year-over-year to $100000.0; the TTM figure through Jun 2025 stood at $100000.0 (down 73.75% YoY), while the FY2024 annual figure was $200000.0, down 95.31% from the prior year.
• Receivables was $100000.0 for Q2 2025 at Calidi Biotherapeutics, roughly flat from $100000.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $4.3 million in Q4 2023 to a low of $870.0 in Q2 2023.
• Historically, Receivables has averaged $720515.7 across 4 years, with a median of $100000.0 in 2025.
• The sharpest annual moves came in 2023 and 2024: Receivables jumped 244727.59% in 2023, then tumbled 95.31% in 2024.
• A 4-year view of Receivables shows it stood at $1740.0 in 2022, then surged by 244727.59% to $4.3 million in 2023, then sank by 95.31% to $200000.0 in 2024, then tumbled by 50.0% to $100000.0 in 2025.
• The last three Receivables figures came in at $100000.0 (Q2 2025), $100000.0 (Q1 2025), and $200000.0 (Q4 2024), per Business Quant data.